IceCure Medical Ltd (ICCM)
Pre-market:
- PR Newswire
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024. The Company will discuss such results and other corporate dev
- PR Newswire
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the Company's CEO, Eyal Shamir, will present via a fireside chat at the A.G.P / Alliance Global Partners' Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 8:20am EDT. Investors may register to view the presentation at the virtual conference thr
- Simply Wall St.
Here's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This Year
Key Insights IceCure Medical to hold its Annual General Meeting on 20th of May CEO Eyal Shamir's total compensation...
